Mirnas as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers
AssigneeBoard of Regents, The University of Texas System
InventorsManjeet K. RAO, Jaafer S. IMAM, Behyar ZOGHI, Yao-Fu CHANG, Panneerdoss SUBBARAYALU
Life of this patent
Estimating the term…
Abstract
Disclosed are methods and compositions for using microRNA (miRNA) for treating cancer. The methods and compositions include hsa-miR-204 and homologs of hsa-miR-204.
Claims32
A method for reducing growth of cancer cells comprising administering an effective amount of a composition comprising hsa-miR-204 and/or a homolog thereof to a subject having or suspected of having cancer cells reduced in expression of hsa-miR-204 and/or a homolog thereof.
-5. (canceled)
(canceled)
-12. (canceled)
-20. (canceled)
-27. (canceled)
A method for identifying a subject likely to benefit from therapy for reducing growth of cancer cells, the method comprising determining the level of hsa-miR-204 and/or a homolog thereof in cells of the subject, wherein the subject is determined as likely to benefit from said therapy when the level of hsa-miR-204 and/or a homolog thereof in the cells of the subject is reduced when compared to a control.
(canceled)
(canceled)
A method for screening for a potential sensitizer and/or de-sensitizer miRNA that, when inhibited, changes the viability of cancer cell line cells cultured in a sub-lethal concentration of a therapeutic active agent, the method comprising:
- culturing cancer cell line cells in a miRNA-inhibitor-containing culture comprising a sub-lethal concentration of the therapeutic active agent together with an inhibitor of the candidate sensitizer miRNA;
- culturing cancer cell line cells in a miRNA-inhibitor-lacking culture comprising the sub-lethal concentration of the therapeutic active agent but lacking added inhibitor of the candidate sensitizer miRNA;
- and
- determining viability of the miRNA-inhibitor-containing cell population and the miRNA-inhibitor-lacking cell population after the period, wherein a candidate sensitizer miRNA is identified as a potential sensitizer miRNA if viability of the miRNA-inhibitor-containing cell population is significantly higher than viability of the miRNA-inhibitor-lacking cell population and wherein a candidate de-sensitizer miRNA is identified as a potential de-sensitizer miRNA if viability of the miRNA-inhibitor-containing cell population is significantly lower than viability of the miRNA-inhibitor-lacking cell population.
-35. (canceled)
(canceled)
(canceled)
-44. (canceled)
A method for reducing growth of cancer cells comprising administering an effective amount of a composition comprising a sensitizer miRNA and/or a homolog thereof to a subject having or suspected of having cancer cells significantly reduced in expression of the sensitizer miRNA and/or a homolog thereof.
A method for reducing growth of cancer cells comprising administering an effective amount of a composition comprising an inhibitor of a de-sensitizer miRNA and/or homolog thereof to a subject having or suspected of having cancer cells significantly increased in expression of an inhibitor of a de-sensitizer miRNA and/or homolog thereof.
A method for identifying a subject likely to benefit from therapy for reducing growth of cancer cells comprising determining the level of a sensitizer miRNA, a sensitizer miRNA homolog, a de-sensitizer miRNA, and/or a de-sensitizer miRNA homolog, or any combination thereof in cells of the subject.
(canceled)
Dependencies are inferred from the claim text.